Alzahrani Abdullah M, Hakami Alqassem Y, AlAzmi Aeshah, Karim Shahid, Ali Ahmed S, Burzangi Abdulhadi S, Alkreathy Huda M, Khan Mansoor A, Alzhrani Rami M, Basudan Samah S, Alzahrani Yahya A
Pharmaceutical Care Department, Ministry of National Guard - Health Affairs, Jeddah, SAU.
Department of Pharmacology, Faculty of Medicine, King Abdulaziz University, Jeddah, SAU.
Cureus. 2022 Sep 25;14(9):e29568. doi: 10.7759/cureus.29568. eCollection 2022 Sep.
Vancomycin administration in individuals with hematological malignancy or neutropenia is associated with a suboptimal trough concentration. Nonetheless, most studies did not distinguish whether low vancomycin trough concentrations were due to hematological malignancies or neutropenia. This study aimed to determine the association between types of hematological malignancy and febrile neutropenia with low vancomycin concentrations.
The present retrospective chart review study was conducted by using clinical data adopted from computerized physician order entries (BestCare®) for all of the patients who received intravenous vancomycin treatment between January 2017 and December 2020 at King Abdulaziz Medical City in Jeddah.
Out of the 296 patients, 217 were included. There was no significant association between the type of hematological malignancy and the incidence of a low trough concentration (p > 0.05), while a significant association between febrile neutropenia and the incidence of a low trough concentration was observed (p < 0.05). Furthermore, the predictors for a low trough among febrile neutropenic patients were creatinine clearance (CrCI) and a low albumin concentration. In addition, there was a significant association between febrile neutropenia and augmented renal clearance (p < 0.05).
The findings of this study conclude that febrile neutropenia is associated with low vancomycin concentrations. Interestingly, augmented renal clearance was observed in most of the febrile neutropenia patients with a significant association, which is considered the main driver for a low trough in neutropenic patients.
在血液系统恶性肿瘤或中性粒细胞减少的个体中给予万古霉素,其谷浓度不理想。然而,大多数研究并未区分低万古霉素谷浓度是由于血液系统恶性肿瘤还是中性粒细胞减少所致。本研究旨在确定血液系统恶性肿瘤类型和发热性中性粒细胞减少与低万古霉素浓度之间的关联。
本回顾性图表审查研究使用了2017年1月至2020年12月期间在吉达阿卜杜勒阿齐兹国王医疗城接受静脉万古霉素治疗的所有患者的计算机化医嘱录入(BestCare®)中的临床数据。
296例患者中,217例被纳入研究。血液系统恶性肿瘤类型与低谷浓度发生率之间无显著关联(p>0.05),而发热性中性粒细胞减少与低谷浓度发生率之间存在显著关联(p<0.05)。此外,发热性中性粒细胞减少患者中低谷浓度的预测因素为肌酐清除率(CrCI)和低白蛋白浓度。此外,发热性中性粒细胞减少与肾脏清除率增加之间存在显著关联(p<0.05)。
本研究结果表明,发热性中性粒细胞减少与低万古霉素浓度有关。有趣的是,在大多数发热性中性粒细胞减少患者中观察到肾脏清除率增加且存在显著关联,这被认为是中性粒细胞减少患者谷浓度低的主要驱动因素。